[{"id":"e32f44a1-6c83-4eeb-afea-f28ff7b0d2a2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03914794","created_at":"2025-08-02T14:12:26.243Z","updated_at":"2025-08-02T14:12:26.243Z","phase":"Phase 2","brief_title":"A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors","source_id_and_acronym":"NCT03914794","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" FGFR3","pipe":"","alterations":" ","tags":["FGFR3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 10/02/2020","start_date":" 10/02/2020","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2025-05-21"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"43f66187-5b30-4357-8f5c-84f785cedc80","acronym":"POD1UM-204","url":"https://clinicaltrials.gov/study/NCT04463771","created_at":"2021-01-18T21:27:26.857Z","updated_at":"2024-07-02T16:34:37.736Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.","source_id_and_acronym":"NCT04463771 - POD1UM-204","lead_sponsor":"Incyte Corporation","biomarkers":" PD-L1 • MSI • POLE","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR • FGFR mutation • FGFR1 mutation","tags":["PD-L1 • MSI • POLE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR • FGFR mutation • FGFR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib) • Zynyz (retifanlimab-dlwr) • epacadostat (INCB024360) • tuparstobart (INCAGN2385) • verzistobart (INCAGN2390)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 01/26/2021","start_date":" 01/26/2021","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-06-06"},{"id":"eb57432c-2617-48dd-9e9e-25c0afd719ac","acronym":"CIBI375A201","url":"https://clinicaltrials.gov/study/NCT04256980","created_at":"2021-01-19T19:16:58.237Z","updated_at":"2024-07-02T16:35:00.136Z","phase":"Phase 2","brief_title":"Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement","source_id_and_acronym":"NCT04256980 - CIBI375A201","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 rearrangement","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 03/03/2020","start_date":" 03/03/2020","primary_txt":" Primary completion: 01/29/2021","primary_completion_date":" 01/29/2021","study_txt":" Completion: 08/31/2023","study_completion_date":" 08/31/2023","last_update_posted":"2024-05-30"},{"id":"23311617-41c6-44fc-9230-357b9b804a7b","acronym":"FIGHT-302","url":"https://clinicaltrials.gov/study/NCT03656536","created_at":"2021-01-19T16:33:21.014Z","updated_at":"2024-07-02T16:35:02.376Z","phase":"Phase 3","brief_title":"A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma","source_id_and_acronym":"NCT03656536 - FIGHT-302","lead_sponsor":"Incyte Corporation","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 rearrangement","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Pemazyre (pemigatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 434","initiation":"Initiation: 06/03/2019","start_date":" 06/03/2019","primary_txt":" Primary completion: 10/26/2027","primary_completion_date":" 10/26/2027","study_txt":" Completion: 07/27/2028","study_completion_date":" 07/27/2028","last_update_posted":"2024-05-21"},{"id":"0147b8e4-e331-432b-853a-2dc46c0ae9a0","acronym":"FIGHT-203","url":"https://clinicaltrials.gov/study/NCT03011372","created_at":"2021-01-18T14:48:52.779Z","updated_at":"2024-07-02T16:35:04.338Z","phase":"Phase 2","brief_title":"A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)","source_id_and_acronym":"NCT03011372 - FIGHT-203","lead_sponsor":"Incyte Corporation","biomarkers":" FGFR1","pipe":" | ","alterations":" FGFR1 rearrangement","tags":["FGFR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 04/25/2017","start_date":" 04/25/2017","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-05-10"},{"id":"5cbd364b-f758-45a6-86eb-66a9228fce4b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06302621","created_at":"2024-03-13T01:30:21.478Z","updated_at":"2024-07-02T16:35:07.278Z","phase":"Phase 1","brief_title":"Pemigatinib + Afatinib in Advanced Refractory Solid Tumors","source_id_and_acronym":"NCT06302621","lead_sponsor":"Massachusetts General Hospital","biomarkers":" FGFR2","pipe":"","alterations":" ","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib) • Pemazyre (pemigatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 07/01/2024","start_date":" 07/01/2024","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-26"},{"id":"d2fff3d6-ffea-4d7d-80f3-4801459b6711","acronym":"","url":"https://clinicaltrials.gov/study/NCT04659616","created_at":"2021-01-19T20:42:17.932Z","updated_at":"2024-07-02T16:35:10.819Z","phase":"Phase 1","brief_title":"Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT04659616","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" TP53 • FLT3 • ABL1 • BCR • EZH2 • RUNX1 • SF3B1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • MLLT3 • CDKN1A • DEK • ZRSR2","pipe":" | ","alterations":" TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • BCOR mutation • Chr del(5q) • STAG2 mutation • FLT3 wild-type • Chr t(9;11) • ZRSR2 mutation","tags":["TP53 • FLT3 • ABL1 • BCR • EZH2 • RUNX1 • SF3B1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • MLLT3 • CDKN1A • DEK • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • BCOR mutation • Chr del(5q) • STAG2 mutation • FLT3 wild-type • Chr t(9;11) • ZRSR2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Pemazyre (pemigatinib) • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-04-09"},{"id":"81518a0a-35de-4448-98f4-4a51c7a1c09f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05004974","created_at":"2021-08-13T12:53:34.296Z","updated_at":"2024-07-02T16:35:15.425Z","phase":"Phase 2","brief_title":"Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05004974","lead_sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","biomarkers":" TNFRSF9","pipe":" | ","alterations":" PD-L1 expression • FGFR1 mutation","tags":["TNFRSF9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • FGFR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • Pemazyre (pemigatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/26/2022","start_date":" 04/26/2022","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-03-11"},{"id":"1f885c20-bddc-441e-b3b3-ce916b0c4eaf","acronym":"FIGHT-209","url":"https://clinicaltrials.gov/study/NCT05267106","created_at":"2022-03-04T15:53:30.724Z","updated_at":"2024-07-02T16:35:22.897Z","phase":"Phase 2","brief_title":"Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations","source_id_and_acronym":"NCT05267106 - FIGHT-209","lead_sponsor":"Incyte Corporation","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 fusion • FGFR1 mutation • FGFR fusion • FGFR2 rearrangement • FGFR1 fusion • FGFR1 rearrangement","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 fusion • FGFR1 mutation • FGFR fusion • FGFR2 rearrangement • FGFR1 fusion • FGFR1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 83","initiation":"Initiation: 05/20/2022","start_date":" 05/20/2022","primary_txt":" Primary completion: 11/29/2024","primary_completion_date":" 11/29/2024","study_txt":" Completion: 11/29/2024","study_completion_date":" 11/29/2024","last_update_posted":"2024-01-19"},{"id":"14f82f5c-e429-4d17-9a3b-88bdc7d125c9","acronym":"ROME","url":"https://clinicaltrials.gov/study/NCT04591431","created_at":"2021-01-19T20:28:32.767Z","updated_at":"2025-02-25T13:53:27.554Z","phase":"Phase 2","brief_title":"The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy","source_id_and_acronym":"NCT04591431 - ROME","lead_sponsor":"Fondazione per la Medicina Personalizzata","biomarkers":" PD-L1 • BRAF","pipe":"","alterations":" ","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Tecentriq (atezolizumab) • erlotinib • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Rozlytrek (entrectinib) • everolimus • lapatinib • Alecensa (alectinib) • Perjeta (pertuzumab) • Iclusig (ponatinib) • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • Talzenna (talazoparib) • Piqray (alpelisib) • Retevmo (selpercatinib) • Alunbrig (brigatinib) • Gavreto (pralsetinib) • Pemazyre (pemigatinib) • ipatasertib (RG7440) • Tepmetko (tepotinib) • itacitinib (INCB039110)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 10/07/2020","start_date":" 10/07/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-10-03"},{"id":"1cfd7d2e-e8fc-43e3-8ada-87dc26bcb0d2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05565794","created_at":"2022-10-04T13:56:42.746Z","updated_at":"2024-07-02T16:35:38.853Z","phase":"Phase 2","brief_title":"Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements","source_id_and_acronym":"NCT05565794","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" FGFR2 • CD4","pipe":" | ","alterations":" FGFR2 fusion","tags":["FGFR2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/11/2022","start_date":" 11/11/2022","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2023-08-28"},{"id":"5ccc7393-ed30-46a9-8b6b-677aebb387d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05997459","created_at":"2023-08-18T15:08:32.931Z","updated_at":"2024-07-02T16:35:39.777Z","phase":"Phase 2","brief_title":"A Single Arm, Phase II Exploratory Clinical Study of Pemitinib in Advanced Gastric Cancer With Previous Standard Therapy Failure the FGFR Variant","source_id_and_acronym":"NCT05997459","lead_sponsor":"Sun Yat-sen University","biomarkers":" FGFR1","pipe":"","alterations":" ","tags":["FGFR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 08/25/2023","start_date":" 08/25/2023","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 03/30/2025","study_completion_date":" 03/30/2025","last_update_posted":"2023-08-17"},{"id":"ebd5d4f3-9c51-4862-880f-738277ea8dc8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05216120","created_at":"2022-02-05T18:27:56.347Z","updated_at":"2024-07-02T16:35:44.081Z","phase":"Phase 2","brief_title":"Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas","source_id_and_acronym":"NCT05216120","lead_sponsor":"HonorHealth Research Institute","biomarkers":" FGFR","pipe":" | ","alterations":" FGFR mutation • FGFR fusion","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/14/2022","start_date":" 06/14/2022","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2023-07-03"},{"id":"f3f16916-e4d8-4dd3-86eb-e3bd81122724","acronym":"","url":"https://clinicaltrials.gov/study/NCT05913661","created_at":"2023-06-22T19:11:39.305Z","updated_at":"2024-07-02T16:35:45.040Z","phase":"Phase 2","brief_title":"Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma","source_id_and_acronym":"NCT05913661","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • Pemazyre (pemigatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/01/2023","start_date":" 07/01/2023","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2023-06-22"},{"id":"ab7410d8-2300-42e7-99c4-950787c11580","acronym":"","url":"https://clinicaltrials.gov/study/NCT02872714","created_at":"2021-01-17T17:44:53.147Z","updated_at":"2024-07-02T16:35:52.533Z","phase":"Phase 2","brief_title":"A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)","source_id_and_acronym":"NCT02872714","lead_sponsor":"Incyte Corporation","biomarkers":" FGFR3 • FGFR","pipe":" | ","alterations":" FGFR3 mutation • FGFR3 fusion","tags":["FGFR3 • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR3 mutation • FGFR3 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib)"],"overall_status":"Completed","enrollment":" Enrollment 263","initiation":"Initiation: 01/12/2017","start_date":" 01/12/2017","primary_txt":" Primary completion: 02/01/2022","primary_completion_date":" 02/01/2022","study_txt":" Completion: 02/01/2022","study_completion_date":" 02/01/2022","last_update_posted":"2023-03-24"},{"id":"89ca258d-eb1d-40cf-a834-fa6461b873b5","acronym":"FIGHT-202","url":"https://clinicaltrials.gov/study/NCT02924376","created_at":"2021-01-17T17:17:39.386Z","updated_at":"2024-07-02T16:35:54.862Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)","source_id_and_acronym":"NCT02924376 - FIGHT-202","lead_sponsor":"Incyte Corporation","biomarkers":" FGFR2 • FGFR","pipe":" | ","alterations":" FGFR2 fusion • FGFR2 rearrangement","tags":["FGFR2 • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion • FGFR2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib)"],"overall_status":"Completed","enrollment":" Enrollment 147","initiation":"Initiation: 01/16/2017","start_date":" 01/16/2017","primary_txt":" Primary completion: 02/01/2022","primary_completion_date":" 02/01/2022","study_txt":" Completion: 02/01/2022","study_completion_date":" 02/01/2022","last_update_posted":"2023-02-23"},{"id":"4c7fe7fb-359b-4d9a-870a-075a8a013607","acronym":"","url":"https://clinicaltrials.gov/study/NCT05560334","created_at":"2022-09-29T15:57:02.923Z","updated_at":"2024-07-02T16:36:03.218Z","phase":"Phase 2","brief_title":"A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations","source_id_and_acronym":"NCT05560334","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/08/2022","start_date":" 09/08/2022","primary_txt":" Primary completion: 09/08/2024","primary_completion_date":" 09/08/2024","study_txt":" Completion: 09/08/2025","study_completion_date":" 09/08/2025","last_update_posted":"2022-09-29"},{"id":"cd6b6ee2-3cf1-4ec5-99e8-127319251246","acronym":"","url":"https://clinicaltrials.gov/study/NCT05287386","created_at":"2022-03-18T11:54:33.970Z","updated_at":"2024-07-02T16:36:15.115Z","phase":"Phase 2","brief_title":"A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy","source_id_and_acronym":"NCT05287386","lead_sponsor":"The First Affiliated Hospital of Xiamen University","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK rearrangement • ROS1 rearrangement","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK rearrangement • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 01/21/2022","start_date":" 01/21/2022","primary_txt":" Primary completion: 01/21/2024","primary_completion_date":" 01/21/2024","study_txt":" Completion: 01/21/2025","study_completion_date":" 01/21/2025","last_update_posted":"2022-03-18"},{"id":"924d9173-6cb5-4543-a610-100f5c86710f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05210946","created_at":"2022-01-29T18:04:55.047Z","updated_at":"2024-07-02T16:36:17.865Z","phase":"","brief_title":"A Single-Arm Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients","source_id_and_acronym":"NCT05210946","lead_sponsor":"The First Affiliated Hospital of Soochow University","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK positive • EGFR T790M • ALK rearrangement • ROS1 rearrangement","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • EGFR T790M • ALK rearrangement • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/06/2021","start_date":" 12/06/2021","primary_txt":" Primary completion: 12/06/2023","primary_completion_date":" 12/06/2023","study_txt":" Completion: 12/06/2024","study_completion_date":" 12/06/2024","last_update_posted":"2022-01-27"},{"id":"9fb82234-c45f-40e2-ae39-a22067e69037","acronym":"","url":"https://clinicaltrials.gov/study/NCT04258527","created_at":"2021-01-18T20:41:48.966Z","updated_at":"2024-07-02T16:36:27.493Z","phase":"Phase 1","brief_title":"Phase 1 Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR Alterations","source_id_and_acronym":"NCT04258527","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" FGFR","pipe":"","alterations":" ","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 03/26/2020","start_date":" 03/26/2020","primary_txt":" Primary completion: 07/02/2020","primary_completion_date":" 07/02/2020","study_txt":" Completion: 03/08/2021","study_completion_date":" 03/08/2021","last_update_posted":"2021-07-23"},{"id":"e2cd3305-5df6-4e09-a219-8e439cbbd335","acronym":"","url":"https://clinicaltrials.gov/study/NCT03235570","created_at":"2021-01-18T15:59:18.609Z","updated_at":"2024-07-02T16:36:44.669Z","phase":"Phase 1","brief_title":"A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)","source_id_and_acronym":"NCT03235570","lead_sponsor":"Incyte Corporation","biomarkers":" FGFR","pipe":"","alterations":" ","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib)"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 08/01/2017","start_date":" 08/01/2017","primary_txt":" Primary completion: 03/04/2020","primary_completion_date":" 03/04/2020","study_txt":" Completion: 03/04/2020","study_completion_date":" 03/04/2020","last_update_posted":"2020-05-29"}]